Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles

Combination therapy is a promising form of treatment. In particular, co-treatment of P3 and QBP1 has been shown to enhance therapeutic effect in vivo in treating polyglutamine diseases. These peptide drugs, however, face challenges in clinical administration due to poor stability, inability to reach...

Full description

Bibliographic Details
Main Authors: Ma Rie Kim, Teng Feng, Qian Zhang, Ho Yin Edwin Chan, Ying Chau
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Polymers
Subjects:
Online Access:https://www.mdpi.com/2073-4360/11/2/288
id doaj-16e842fe5d0d4611ba0f4b2e34b24e04
record_format Article
spelling doaj-16e842fe5d0d4611ba0f4b2e34b24e042020-11-24T22:06:39ZengMDPI AGPolymers2073-43602019-02-0111228810.3390/polym11020288polym11020288Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric NanoparticlesMa Rie Kim0Teng Feng1Qian Zhang2Ho Yin Edwin Chan3Ying Chau4Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, ChinaDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, ChinaSchool of Life Sciences, Faculty of Science, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, ChinaSchool of Life Sciences, Faculty of Science, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, ChinaDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, ChinaCombination therapy is a promising form of treatment. In particular, co-treatment of P3 and QBP1 has been shown to enhance therapeutic effect in vivo in treating polyglutamine diseases. These peptide drugs, however, face challenges in clinical administration due to poor stability, inability to reach intracellular targets, and lack of method to co-deliver both drugs. Here we demonstrate two methods of co-encapsulating the peptide drugs via polymer poly(ethylene glycol)-block-polycaprolactone (PEG-b-PCL) based nanoparticles. Nanoparticles made by double emulsion were 100⁻200 nm in diameter, with drug encapsulation efficiency of around 30%. Nanoparticles made by nanoprecipitation with lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (POPG) were around 250⁻300 nm in diameter, with encapsulation efficiency of 85⁻100%. Particles made with both formulations showed cellular uptake when decorated with a mixture of peptide ligands that facilitate endocytosis. In vitro assay showed that nanoparticles could deliver bioactive peptides and encapsulation by double emulsion were found to be more effective in rescuing cells from polyglutamine-induced toxicity.https://www.mdpi.com/2073-4360/11/2/288co-encapsulationco-deliverynanoparticlespeptide deliverypolymeric drug delivery systemdouble emulsion-solvent evaporation technique(s)
collection DOAJ
language English
format Article
sources DOAJ
author Ma Rie Kim
Teng Feng
Qian Zhang
Ho Yin Edwin Chan
Ying Chau
spellingShingle Ma Rie Kim
Teng Feng
Qian Zhang
Ho Yin Edwin Chan
Ying Chau
Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles
Polymers
co-encapsulation
co-delivery
nanoparticles
peptide delivery
polymeric drug delivery system
double emulsion-solvent evaporation technique(s)
author_facet Ma Rie Kim
Teng Feng
Qian Zhang
Ho Yin Edwin Chan
Ying Chau
author_sort Ma Rie Kim
title Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles
title_short Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles
title_full Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles
title_fullStr Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles
title_full_unstemmed Co-Encapsulation and Co-Delivery of Peptide Drugs via Polymeric Nanoparticles
title_sort co-encapsulation and co-delivery of peptide drugs via polymeric nanoparticles
publisher MDPI AG
series Polymers
issn 2073-4360
publishDate 2019-02-01
description Combination therapy is a promising form of treatment. In particular, co-treatment of P3 and QBP1 has been shown to enhance therapeutic effect in vivo in treating polyglutamine diseases. These peptide drugs, however, face challenges in clinical administration due to poor stability, inability to reach intracellular targets, and lack of method to co-deliver both drugs. Here we demonstrate two methods of co-encapsulating the peptide drugs via polymer poly(ethylene glycol)-block-polycaprolactone (PEG-b-PCL) based nanoparticles. Nanoparticles made by double emulsion were 100⁻200 nm in diameter, with drug encapsulation efficiency of around 30%. Nanoparticles made by nanoprecipitation with lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (POPG) were around 250⁻300 nm in diameter, with encapsulation efficiency of 85⁻100%. Particles made with both formulations showed cellular uptake when decorated with a mixture of peptide ligands that facilitate endocytosis. In vitro assay showed that nanoparticles could deliver bioactive peptides and encapsulation by double emulsion were found to be more effective in rescuing cells from polyglutamine-induced toxicity.
topic co-encapsulation
co-delivery
nanoparticles
peptide delivery
polymeric drug delivery system
double emulsion-solvent evaporation technique(s)
url https://www.mdpi.com/2073-4360/11/2/288
work_keys_str_mv AT mariekim coencapsulationandcodeliveryofpeptidedrugsviapolymericnanoparticles
AT tengfeng coencapsulationandcodeliveryofpeptidedrugsviapolymericnanoparticles
AT qianzhang coencapsulationandcodeliveryofpeptidedrugsviapolymericnanoparticles
AT hoyinedwinchan coencapsulationandcodeliveryofpeptidedrugsviapolymericnanoparticles
AT yingchau coencapsulationandcodeliveryofpeptidedrugsviapolymericnanoparticles
_version_ 1725822571856789504